Biomedical subjects
Publications and source records attributed to J Novak.
We present a 24-hour time-lapse videosequence of in vitro behavior of Hep-2 cells treated with 10 m g/ml Etoposide, a topoisomerase II inhibitor. The cell behavior was recorded by a Mitsubishi video recorder, HS-S5600. In the presented sequence, we show the typical cell rounding accompanied by formation of numerous pseudopodia and rapid rhythmical contractions, so called membrane blebbing known as "dance of death".
(+)-cis-Sabinene hydrate and (+)-trans-sabinene hydrate are the main monoterpenes found in marjoram (Origanum majorana), but can also be found in other Origanum species as well, as in e.g. Melaleuca alternifolia. The synthesis of sabinene hydrate in marjoram (Origanum majorana) is performed by sabinene hydrate synthase. It is claimed, that both, (+)-cis- and (+)-trans-sabinene hydrate are produced by the same enzyme in an exact ratio of 10:1. To verify this in vitro result in vivo, we analysed single plants of 20 different genotypes of Origanum majorana and of three different populations of Origanum microphyllum and calculated the ratios of (+)-cis- to (+)-trans-sabinene hydrates. In Origanum majorana a constant ratio of 20:1 could be found, whereas in Origanum microphyllum the ratio did not prove to be constant.
Mutacin II is a post-translationally modified lantibiotic peptide secreted by Streptococcus mutans T8, which inhibits the energy metabolism of sensitive cells. The deduced amino acid sequence of promutacin II is NRWWQGVVPTVSYECRMNSWQHVFTCC, which is capable of forming three thioether bridges. It was not obvious, however, how the three thioether bridges are organized. To examine the bridging, the cyanogen bromide cleavage products of mutacin II and its variants generated by protein engineering, C15A, C26A, and C15A/C26A, were analyzed by mass spectrometry. Analysis of the wild type molecule and the C15A variant excluded several possibilities and also indicated a high fidelity of formation of the thioether bridges. This allowed us to further resolve the structure by analysis (mass spectrometry and tandem mass spectrometry) of the cyanogen bromide cleavage fragments of the C26A and C15A/C26A mutants. Nuclear magnetic resonance analysis established the presence of one and two dehydrobutyrine residues in mutacin II and the C15A variant, respectively, thus yielding the final structure. The results of this investigation showed that the C-terminal part contains three thioether bridges connecting Cys residues 15, 26, and 27 to Ser/Thr residues 10, 12 and 19, respectively, with Thr(25) being modified to dehydrobutyrine.
PAHdb is an online relational locus-specific "mutation database" (http://www.mcgill.ca/pahdb) for the human phenylalanine hydroxylase gene (symbol PAH) and its associated phenotypes (protein, metabolic, clinical). When combined with associated information (population distribution of allele, haplotype association, etc.) PAHdb functions as a knowledgebase. From the outset, and in the absence of raw data (e.g., sequence gels), PAHdb has instead been an annotated repository of information about mutations maintained by a team of curators. It is also disease-oriented, being focused on a variant phenotype (hyperphenylalaninemia (HPA) and its most important form of disease, phenylketonuria (PKU)) resulting from primary dysfunction of the PAH enzyme (EC 1.14.16.1); it is "patient friendly" in that it contains information for those personally involved with HPA/PKU (MIM# 261600). PAHdb also serves its community through direct interaction.
We report a rare and, to our knowledge, as yet undescribed type of collision tumour - rectal leiomyosarcoma and prostate adenocarcinoma. Our study also provides the first data on molecular alterations [polymerase chain reaction/loss of heterozygosity (LOH) analysis] of the APC, NF-1, DCC, p53, nm23-H1 and BRCA-1 genes in the two components of the collision tumour. None of the genes examined in this study expressed LOH in the prostate carcinoma component of the collision tumour. By contrast, in the leiomyosarcoma component, LOH was found at the DCC and p53 genes, proving that these two tumours did not arise from the same stem cell but represent two different neoplastic growths.
Explore the source record for details and available documents.
OBJECTIVES: To determine whether nicotine affects the proliferation and expression of the bombesin-like peptide autocrine system in human small cell lung carcinoma (SCLC) SHP77 cells compared with nonmalignant human bronchial epithelial BEAS 2B cells as non-neuroendocrine controls. METHODS: Human lung cells were cultured in defined serum-free medium with various concentrations of nicotine added for various times. Proliferation was measured by cell counts and colorimetric assay, bombesin-like peptide receptor expression was assayed by specific binding assays and quantitative competitive PCR, and bombesin-like peptides determined by ELISA. RESULTS: Nicotine significantly stimulated the growth of human SCLC SHP77 and NCI-H865 cells, but not BEAS 2B cells. Bombesin-like peptide receptor specific binding and mRNA expression were not affected by nicotine exposure in SHP77 cells or BEAS 2B cells. An increase in SHP77 cellular bombesin-like peptide content was observed. CONCLUSIONS: Human SCLC SHP77 cells express the components of the bombesin-like peptide autocrine system. Increased proliferation in the presence of nicotine may be due in part to increased levels of bombesin-like peptides in SHP77 cultured in nicotine. Nicotine effects on nonmalignant pulmonary neuroendocrine cells may provide additional insight into how nicotine itself may promote lung carcinogenesis.
Explore the source record for details and available documents.
Mutacin II is a ribosomally synthesized peptide lantibiotic produced by group II Streptococcus mutans. DNA sequencing has revealed that the mutacin II biosynthetic gene cluster consists of seven specific open reading frames: a regulator (mutR), the prepromutacin structural gene (mutA), a modifying protein (mutM), an ABC transporter (mutT), and an immunity cluster (mutFEG). Transformations of a non-mutacin-producing strain, S. mutans UA159, and a mutacin I-producing strain, S. mutans UA140, with chromosomal DNA from S. mutans T8 with an aphIII marker inserted upstream of the mutacin II structural gene yielded transformants producing mutacin II and mutacins I and II, respectively.
Chronic aldosterone (Aldo) excess is associated with transient sodium retention, extracellular fluid volume expansion, renal vasodilation, and hypertension. The purpose of this study was to determine the role of nitric oxide (NO) in mediating the renal vasodilation and the escape from the sodium-retaining actions of Aldo. To achieve this goal, we examined the long-term effects of Aldo (15 microgram. kg-1. min-1 for 7 days) in conscious, chronically instrumented control dogs (n = 9) and in dogs (n = 12) pretreated with the NO synthesis inhibitor NG-nitro-L-arginine methyl ester (L-NAME; 10 microgram. kg-1. min-1). In control dogs, Aldo caused a transient sodium retention (126 +/- 6 to 56 +/- 2 meq/day) followed by a return of sodium excretion to normal levels. Aldo also increased renal plasma flow by 15% (205 +/- 13 to 233 +/- 16 ml/min), glomerular filtration rate by 20% (72 +/- 3 to 87 +/- 5 ml/min), and arterial pressure from 90 +/- 3 to 102 +/- 3 mmHg. Aldo increased urinary nitrate/nitrite excretion by 60% in the control dogs. Although the sodium-retaining (144 +/- 7 to 56 +/- 7 meq/day) and arterial pressure (122 +/- 6 to 136 +/- 5 mmHg) responses to Aldo were the same in dogs pretreated with L-NAME compared with control, the renal hemodynamic response was markedly attenuated. The results of this study suggest that NO plays an important role in mediating the renal vasodilation during chronic Aldo excess.
We have previously found that the vascular responsiveness to alpha1-adrenergic agonists is reduced in pregnant rats and enhanced in a rat model of pregnancy-induced hypertension produced by chronic treatment of pregnant rats with the nitric oxide (NO) synthase inhibitor NG-nitro-L-arginine methyl ester (L-NAME). The purpose of this study was to investigate whether the observed changes in vascular reactivity during normal pregnancy and during pregnancy-induced hypertension reflect changes in the mechanisms of Ca2+ entry into vascular smooth muscle. 45Ca2+ influx and active stress during alpha1-adrenergic stimulation by phenylephrine and membrane depolarization by 96 mM KCl were measured in deendothelialized aortic strips isolated from virgin and pregnant Sprague-Dawley rats untreated or treated with 1 mg/day L-NAME for 4-6 days and incubated in Krebs solution containing increasing concentrations of extracellular Ca2+ ([Ca2+]e). In all groups of rats, both phenylephrine and 96 mM KCl caused [Ca2+]e-dependent increases in active stress and 45Ca2+ influx. The phenylephrine- and 96 mM KCl-induced active stress and Ca2+ influx were significantly reduced in pregnant rats but significantly enhanced in pregnant rats treated with L-NAME. The phenylephrine-induced Ca2+ influx-stress relationship was significantly greater than that induced by 96 mM KCl in pregnant rats treated with L-NAME. The phenylephrine-induced Ca2+ influx-stress relationship was reduced in pregnant rats but enhanced in pregnant rats treated with L-NAME. Chronic treatment with L-NAME had minimal effect on active stress, Ca2+ influx, and the Ca2+ influx-stress relationship in virgin rats. These results provide evidence that the mechanisms of Ca2+ entry into vascular smooth muscle are inhibited during pregnancy but enhanced during inhibition of NO synthesis in late pregnancy. The enhancement of the phenylephrine-induced Ca2+ influx-stress relationship in pregnant rats treated with L-NAME suggests activation of other contractile mechanisms in addition to stimulation of Ca2+ entry. These mechanisms appear to be inhibited during normal pregnancy.
Alterations in nitric oxide (NO) production have been suggested to play a role in mediating changes in renal function during normal pregnancy and in pregnancy-induced hypertension. Although NO production is enhanced during normal pregnancy, the mechanisms for the increase are unknown. The purpose of this study was to determine whether the elevation in NO production during pregnancy is associated with increases in renal expression of endothelial (eNOS), inducible (iNOS), and neuronal (nNOS) nitric oxide synthases. To achieve this goal we examined systemic and renal hemodynamics, urinary excretion of nitrate/nitrite, and renal protein expression of the three NOS isoforms in prepregnant rats, pregnant rats at days 6, 13, and 19 of gestation and at day 4 postpartum. Mean arterial pressure decreased by 14% in late pregnancy whereas the glomerular filtration rate and renal plasma flow increased by 21% and 24%, respectively, in mid pregnancy. Excretion of nitrate/nitrite increased throughout pregnancy with a 3.4-fold increase present at day 19 (12.2+/-0.7 to 41.1+/-1.3 micromol/24 h). Renal eNOS protein expression decreased by 39% during pregnancy with the lowest level resulting at day 19 and returning to virgin levels by day 4 post partum. In contrast, renal iNOS and nNOS protein expression increased 31% and 25%, respectively, with highest expression occurring for both at day 13 of pregnancy. These data suggest that the increased NO production and renal hemodynamics associated with pregnancy in rats may be caused by the upregulation of iNOS and nNOS in the kidney.
Circulating immune complexes (CICs) isolated from sera of patients with IgA nephropathy (IgAN) consist of undergalactosylated, mostly polymeric, and J chain-containing IgA1 and IgG antibodies specific for N-acetylgalactosamine (GalNAc) residues in O-linked glycans of the hinge region of IgA1 heavy chains. Antibodies with such specificity occur in sera of IgAN patients, and in smaller quantities in patients with non-IgA proliferative glomerulonephritis and in healthy controls; they are present mainly in the IgG (predominantly IgG2 subclass), and less frequently in the IgA1 isotype. Their specificity for GalNAc was determined by reactivity with IgA1 myeloma proteins with enzymatically removed N-acetylneuraminic acid (NeuNAc) and galactose (Gal); removal of the O-linked glycans of IgA1 resulted in significantly decreased reactivity. Furthermore, IgA2 proteins that lack the hinge region with O-linked glycans but are otherwise structurally similar to IgA1 did not react with IgG or IgA1 antibodies. The re-formation of isolated and acid-dissociated CICs was inhibited more effectively by IgA1 lacking NeuNAc and Gal than by intact IgA1. Immobilized GalNAc and asialo-ovine submaxillary mucin (rich in O-linked glycans) were also effective inhibitors. Our results suggest that the deficiency of Gal in the hinge region of IgA1 molecules results in the generation of antigenic determinants containing GalNAc residues that are recognized by naturally occurring IgG and IgA1 antibodies.
Despite 31 years of clinical and laboratory investigation, the pathogenesis of IgAN remains largely enigmatic. However, it seems clear that IgA1 accumulates in the glomerular mesangia due to a systemic process rather than an abnormality intrinsic in the kidney. Based on recent studies, investigators have proposed a wide range of pathogenetic mechanisms: nonspecific attachment because excessive IgA1 is synthesized in a short or prolonged immune response, increased binding due to an IgA-specific receptor (perhaps with altered characteristics) on mesangial cells, and increased glomerular deposition because an abnormal structure of the antibody (particularly of the glycan moieties in the hinge region) allows it to escape its normal degradative pathways or facilitates binding to a receptor on mesangial cells. Whether one or more of these postulates fully explains IgAN remains to be determined. Until then, treatment of the many affected patients worldwide will continue to lack a disease-specific approach.
Explore the source record for details and available documents.
Streptococcus mutans, along with many other gram-positive bacteria produce small antibacterial peptides called bacteriocins. Bacteriocins elaborated by S. mutans, termed mutacins, may provide a selective force necessary for initial or sustained colonization in dental plaque by this major dental pathogen. Previously, we purified and characterized mutacin II, the first lantibiotic found in S. mutans. Specific oligonucleotides designed according to the N-terminal amino acid sequence permitted amplification of 0.7 kb upstream and 2.1 kb downstream of the N-terminus, using single-specific-primer PCR (SSP-PCR). The gene encoding the mutacin II prepeptide, mutA, was subsequently cloned and sequenced. The complete prepeptide consists of 53 amino acids, including the 26 amino acid amphipathic leader peptide with the Gly(-2)-Gly(-1) sequence at the processing site. The prepeptide showed similarity to the lantibiotics lacticin 481, variacin, salivaricin and streptococcin A-FF22. A 3 kb open reading frame immediately downstream of mutA, denoted mutM, showed sequence similarities to LCNDR2 from Lactococcus lactis. By analogy, mutM is probably involved in post-translational modification of the mutacin prepeptide. Gene disruption with an insertional vector pVA891 showed that intact copies of mutA and mutM are required for production of mutacin II.
Many dental and periodontal diseases are largely a question of bacterial etiology. Dental caries develop due to an increase of strongly acidogenic and aciduric gram-positive bacteria while common forms of periodontal disease are linked to anaerobic gram-negative bacteria in subgingival plaque. Many plants and plant-derived antimicrobial components are used in folklore therapeutics for the treatment of periodontal disorders and for the purposes of oral hygiene. Some have been evaluated for possible use in modern medicine, while thousands of other potentially useful/plants have not been tested. In this study, we evaluated the feasibility of screening for antibacterials isolated from plants with activity against three representatives of oral streptococci. We developed and tested the following methodologies: (1) Extraction of antibacterial components from plants; (2) Assays for antibacterial activity; (3) Chromatographic methods for initial analysis of compounds of interest. The screening process for plant antimicrobials consisted of extraction of plant material and assay of antibacterial activity using a spotting test with the selected oral streptococci as indicator strains. In addition, we developed chromatographic procedures that allow characterization and optimization of initial isolation steps. Depending on the indicator microorganisms used, the screening assay can target additional pathogens including other streptococci (group A and B, and pneumococci) and periodontal pathogens such as Porphyromonas. Also, we noted that the activity of some extracts varied against different oral bacteria. Our conclusion, supported by extensive data, was that the screening for antimicrobials from plants is a feasible approach to the identification of natural compounds with antimicrobial properties against dental pathogens.
Mutacin II, elaborated by group II Streptococcus mutans, is a ribosomally synthesized and posttranslationally modified polypeptide antibiotic containing unusual thioether and didehydro amino acids. To ascertain the role of specific amino acid residues in mutacin II antimicrobial activity, we developed a streptococcal expression system that facilitates the replacement of the mutA gene with a single copy of a mutated variant gene. As a result, variants of mutacin II can be designed and expressed. The system was tested by constructing the following mutant peptides: delta N1, V7A, P9A, T10A, T10S, C15A, C26A, and C27A. All of these mutacin II variants except delta N1 and T10A, which were not secreted, were isolated, and their identities were verified by mass spectrometry. Variants P9A, C15A, C26A, and C27A failed to exert antimicrobial activity. Because the P9A and T10A variants comprise the "hinge" region of mutacin II, these observations suggest that in addition to the thioether and didehydro amino acids, the hinge region is essential for biological activity and biosynthesis or export of the peptide. Tandem mass spectrometry of the N-terminal part of the wild-type molecule and its C15A variant confirmed that the threonine at position 10 is dehydrated and present as a didehydrobutyrine residue. This analysis of the active T10S variant further suggested that a didehydro amino acid at this position is specific for antimicrobial activity and that the biosynthetic machinery does not discriminate between threonine and serine. In contrast, the lack of production of mutacin variants with alanine substituted for threonine at position 10, as well as the deletion of asparagine at the N terminus (delta N1), indicates that specific residues in the propeptide may be crucial for certain steps in the biosynthetic pathway of this lantibiotic.